Día Mundial de la Trombosis

Each Year One in Four People Die from Conditions Caused By Thrombosis. On World Thrombosis Day, Viatris Showcases the Importance of Partnerships To Support Increased Disease Awareness And Recovery

Each Year One in Four People Die from Conditions Caused By Thrombosis. 
On World Thrombosis Day, Viatris Showcases the Importance of Partnerships To Support Increased Disease Awareness And Recovery 
 

Being in a hospital is one of the highest risk factors of developing Thrombosis, commonly referred to as blood clots, with half of hospitalized patients being affected. When preventive measures are used in hospitals, the risk is reduced significantly.

Appropriate prophylaxis in high-risk medically ill patients has been shown to reduce risk of venous thromboembolism (VTE) and related mortality.

October 12 – Each year, one in four people worldwide die from conditions caused by thrombosis ; this is more than AIDS, breast cancer, prostate cancer and motor vehicle crashes combined . At the same time, research suggests that venous thrombo-embolic events are often preventable, and prevention strategies can stop the development of clots in 'at-risk' individuals.
 
Using the occasion of World Thrombosis Day – marked each year on October 13 – Viatris, a global healthcare company, highlights the importance of partnerships in order to support patient needs in the field of thrombosis.
 
Viatris is partnering with key medical societies, such as the International Society on Thrombosis and Haemostasis (ISTH) to support World Thrombosis Day. The company is also a supporter of the European Society of Intensive Care Medicine (ESICM) and of the European Society for Vascular Surgery (ESVS) board member (prof. Kakkos) on educational webinars for healthcare professionals. 
 
Viatris also builds partnerships with patient advocacy groups and civic associations, such as with the Active Citizenship Network (closely working with the European Commission) in supporting activities with the ultimate goal to provide indications and recommendations to European Institutions and relevant stakeholders on how to limit the future impact of Covid-19, like emergencies for chronic patients, simplifying procedures and facilitating their access to medical services in order to achieve a significant shift in care delivery.
 
Shaantanu Donde, Head of Portfolio Management, in Viatris’ Medical Affairs team - Developed Markets, said: „Creating a stronger support network benefits patients across the globe, which ties into Viatris mission to empower people worldwide to live healthier at every stage of life. In the area of thrombosis, we connect with stakeholders to support their work on increasing disease awareness, but also in terms of recovery support.” 
 
At the same time, it is not well recognized that the risk of venous-thromboembolism (VTE) in many hospitalized medically ill patients is at least as high as in populations after surgery. This may partly be attributed to the clinically silent nature of VTE in many patients, and the difficulty in predicting which patients might develop symptoms or fatal pulmonary embolism . 
 
Professor Laurent Bertoletti, University Hospital of Saint-Etienne, France, said: “With up to 25 percent of patients dying of conditions caused by thrombo-embolism, prevention and proper follow up measures taken in hospital are key. Any hospitalized patient is potentially at risk for blood clots, and all physicians should take the necessary time to perform the thrombosis risk assessment to identify at-risk patients. Optimal follow-up is also needed after a VTE episode, making it possible to propose dedicated therapy to patients with potentially severe VTE sequels.”
 
“Women have increased risk of getting a blood clot – such as through pregnancy or after a C-section. But blood clots are preventable in many cases, very treatable if caught on time but potentially fatal if the symptoms are ignored’, Said Prof. dr. Saskia Middeldorp, Head Department of Internal Medicine Radboud UMC, Netherlands. “Loosing weight, staying active, smoke cessation and generally keeping a healthy lifestyle help diminish the risk of getting into complications when people are admitted  in hospital. Raising awareness around preventing clots is especially important as this year the World Thrombosis Day campaign sheds light into the hospital-associated thrombosis.”, she added. 
 
Viatris World Thrombosis Day campaign
For the World Thrombosis Day, Viatris is sharing the story of Shazia Khan, a Viatris employee in the UK having dealt with venous thrombo-embolism herself. Her story touches on prevention mechanisms, and demonstrates the support Shazia got from Thrombosis Ireland, a patient association, through her recovery.
 
 
Patient’ recovery after a venous thrombo-embolism is also the main theme of the World Thrombosis Day organization in 2022.
 
Shazia is now passionate about raising awareness for both patients and doctors, to make sure they do not miss the signs of thrombosis, and to support patients like her.
 
Key Facts about Thrombosis 
  • Every year, there are approximately 10 million cases of venous thromboembolism (VTE) worldwide ; in Europe only, there are 544,000 VTE-related deaths every year .
  • Half of medically ill patients are assessed as having high VTE risk and require prophylaxis; of these, only 1 in 2 patients actually got adequate prophylaxis – with Europe scoring slightly better than rest of the world. 
  • Thrombosis is as frequent in men and women , and is more frequent in older patients. 
Preventing thromboembolism for hospitalized patients 
  • Patients hospitalized with medical conditions who have congestive heart failure, chronic obstructive lung disease, cancer, a history of venous thromboembolism, or certain other conditions are at increased risk of venous thromboembolism while they are hospitalized.
  • The American Society of Hematology (ASH) evidence-based Clinical Practice Guidelines (2018) recommends thromboprophylaxis of high-risk medical patients while they are hospitalized – and not only for patients undertaking a surgery. 
  • VTE remains highly prevalent in medically ill patients, and often leads to increased mortality and cost burden during hospitalization and post-discharge. Nearly half of all VTEs occur during or after hospitalization, with pulmonary embolism accounting for 10% of inpatient mortality .
  • Appropriate prophylaxis in high-risk medically ill patients has been shown to reduce risk of VTE and related mortality. Despite current evidence-based guidelines, VTE prophylaxis has been under-used .
  • For hospitalized medical patients who are acutely ill at increased risk of thrombosis, anticoagulant thromboprophylaxis with low-molecular-weight heparin (LMWH), unfractionated heparin, or fondaparinux was recommended by ASH in 2018. 
 
With its thrombosis portfolio, Viatris is one of the largest suppliers of products in Europe. 
 
About Viatris
Viatris Inc. (NASDAQ: VTRS), is a global pharmaceutical company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a portfolio of biosimilars and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube
 
 
 
 

[1] By 66% - Forgo paper 2021

[1]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140153/#:~:text=Venous%20thromboembolism%20(VTE)%20remains%20highly,for%2010%25%20of%20inpatient%20mortality.

[1] WTD/ subunit of ISTH https://www.worldthrombosisday.org/

[1] WTD/ subunit of ISTH https://www.worldthrombosisday.org/; in the US

[1] Prevention of venous-thromboembolism in medically ill patients: a clinical update; Alexander G G Turpie, Alain Leizorovicz, p 807; www.postgradmedj.com

[1] WTD/ subunit of ISTH https://www.worldthrombosisday.org/

[1] WTD/ subunit of ISTH https://www.worldthrombosisday.org/

[1] 66% of patients got adequate prophylaxis in Europe; Forgo 2021 paper

[1] https://link.springer.com/article/10.1007/s10654-021-00813-w

[1] Heit J Nat Rev Cardiol. 2015 August ; 12(8): 464–4

[1] WTD/ subunit of ISTH https://www.worldthrombosisday.org/

[1] WTD/ subunit of ISTH https://www.worldthrombosisday.org/

[1]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140153/#:~:text=Venous%20thromboembolism%20(VTE)%20remains%20highly,for%2010%25%20of%20inpatient%20mortality.

[1] Kahn S.R. Lim W. Dunn A.S. et al. Prevention of VTE in non-surgical patients: antithrombotic therapy and prevention of thrombosis

Powered by Translations.com GlobalLink OneLink Software